15-04-2025
TD Cowen Remains a Hold on Pfizer (PFE)
TD Cowen analyst Steve Scala maintained a Hold rating on Pfizer (PFE – Research Report) today and set a price target of $32.00. The company's shares closed yesterday at $22.12.
Stay Ahead of the Market:
Discover outperforming stocks and invest smarter with Top Smart Score Stocks.
Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener.
Scala covers the Healthcare sector, focusing on stocks such as Merck & Company, Pfizer, and AstraZeneca. According to TipRanks, Scala has an average return of 4.2% and a 55.62% success rate on recommended stocks.
In addition to TD Cowen, Pfizer also received a Hold from Citi's Geoff Meacham in a report issued today. However, yesterday, Jefferies maintained a Buy rating on Pfizer (NYSE: PFE).
Based on Pfizer's latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $17.76 billion and a net profit of $410 million. In comparison, last year the company earned a revenue of $14.25 billion and had a GAAP net loss of $3.34 billion
Based on the recent corporate insider activity of 27 insiders, corporate insider sentiment is neutral on the stock. Last month, JENNIFER B. DAMICO, the SVP & Controller of PFE sold 3,249.00 shares for a total of $84,373.90.
